...
首页> 外文期刊>Cytopathology >Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study
【24h】

Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study

机译:EGFR突变体特异性抗体在不同细胞制剂中的性能:一项验证研究

获取原文
获取原文并翻译 | 示例
           

摘要

ObjectivesMolecular testing for epidermal growth factor receptor (EGFR) mutations is required to select the most appropriate treatment for advanced-stage non-small cell lung cancer (NSCLC). In routine practice, cytological samples are often the only specimens available for testing. When the number of neoplastic cells is large, DNA-based assays are the gold standard. When cytological samples contain only a few neoplastic cells, immunocytochemistry (ICC) using anti-EGFR mutant-specific antibodies may be more effective. We aim to assess the specificity and sensitivity of IHC staining in cytological specimens using mutated cell lines subjected to different cytopreparations and staining methods.
机译:目的需要对表皮生长因子受体(EGFR)突变进行分子检测,以选择最合适的晚期非小细胞肺癌(NSCLC)治疗方法。在常规实践中,细胞学样本通常是唯一可用于测试的样本。当赘生性细胞的数量很大时,基于DNA的测定法就是金标准。当细胞学样品仅包含少数肿瘤细胞时,使用抗EGFR突变体特异性抗体的免疫细胞化学(ICC)可能更有效。我们的目的是使用经过不同细胞制备和染色方法的突变细胞系评估IHC染色在细胞学标本中的特异性和敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号